Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease-Reference-Cited by-同舟云学术

Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease

Published:2018-10-02 Issue:2 Volume:21 Page:285-292
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Shimizu Masanori¹,Suzuki Kunihiro²,Kato Kanako¹,Jojima Teruo¹,Iijima Toshie¹,Murohisa Toshimitsu³,Iijima Makoto³,Takekawa Hidehiro⁴,Usui Isao¹,Hiraishi Hideyuki³,Aso Yoshimasa^ORCID

Affiliation:

1. Department of Endocrinology and Metabolism; Dokkyo Medical University; Tochigi Japan

2. Oyama East Clinic; Tochigi Japan

3. Department of Gastroenterology; Dokkyo Medical University; Tochigi Japan

4. Centre of Medical Ultrasonics; Dokkyo Medical University; Tochigi Japan

Funder

Ono

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13520/fullpdf

Reference34 articles.

1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO);J Hepatol.,2016

2. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years;Wong;Gut,2010

3. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis;Ascha;Hepatology,2010

4. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study;Williamson;Diabetes Care,2011

5. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers;Vilar-Gomez;J Hepatol,2018

Cited by 270 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

2. Impact of Visceral and Hepatic Fat on Cardiometabolic Health;Current Cardiology Reports;2024-09-05

3. Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study;Diabetes, Obesity and Metabolism;2024-09-02

4. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease;Hormones;2024-08-07

5. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies;Chinese Journal of Natural Medicines;2024-08